Page last updated: 2024-11-07

a 71623

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

A 71623: structure given in first source; a cholecystokinin-A receptor agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID121964
CHEMBL ID323521
CHEMBL ID337366
MeSH IDM0181926

Synonyms (26)

Synonym
gtpl858
PDSP2_000865
a71623
PDSP1_000879 ,
chembl323521 ,
chembl337366
a-71623
3-[2-[2-tert-butoxycarbonylamino-3-(1h-indol-3-yl)-propionylamino]-6-(3-o-tolyl-ureido)-hexanoylamino]-n-(1-carbamoyl-2-phenyl-ethyl)-n-methyl-succinamic acid
bdbm50003666
(3s)-4-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-[[(2s)-2-[[(2s)-3-(1h-indol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]-6-[(2-methylphenyl)carbamoylamino]hexanoyl]amino]-4-oxobutanoic acid
l-phenylalaninamide, n-((1,1-dimethylethoxy)carbonyl)-l-tryptophyl-n6-(((2-methylphenyl)amino)carbonyl)-l-lysyl-l-alpha-aspartyl-nalpha-methyl-
a 71623
130408-77-4
boc-trp-lys(epsilon-n-2-methylphenylaminocarbonyl)-asp-(n-methyl)-phe-nh2
n-[(1,1-dimethylethoxy)carbonyl]-l-tryptophyl-n6-[[(2-methylphenyl)amino]carbonyl]-l-lysyl-l-?-aspartyl-n?-methyl-l-phenylalaninamide
AKOS024457082
J-005804
DTXSID70926728
n~2~-(2-{[2-{[tert-butoxy(hydroxy)methylidene]amino}-1-hydroxy-3-(1h-indol-3-yl)propylidene]amino}-1-hydroxy-6-{[hydroxy(2-methylanilino)methylidene]amino}hexylidene)-n-(1-hydroxy-1-imino-3-phenylpropan-2-yl)-n-methyl-alpha-asparagine
(6s,9s,12s)-6-((1h-indol-3-yl)methyl)-12-(((s)-1-amino-1-oxo-3-phenylpropan-2-yl)(methyl)carbamoyl)-2,2-dimethyl-4,7,10-trioxo-9-(4-(3-(o-tolyl)ureido)butyl)-3-oxa-5,8,11-triazatetradecan-14-oic acid
Q27074078
l-phenylalaninamide, n-[(1,1-dimethylethoxy)carbonyl]-l-tryptophyl-n6-[[(2-methylphenyl)amino]carbonyl]-l-lysyl-l-alpha-aspartyl-nalpha-methyl-
cid 121964
MS-31558
CS-0027708
HY-P1096

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"37 microM, indicating high bioavailability and favorable partitioning and distribution effects from the sublingual cavity for this formulation."( Alternate drug delivery routes for A-71623, a potent cholecystokinin-A receptor agonist tetrapeptide.
Adjei, LA; Cannon, JB; Garren, K; Lu, MY, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cholecystokinin receptor type ARattus norvegicus (Norway rat)IC50 (µMol)0.00000.00000.43624.3000AID53040
Cholecystokinin receptor type ARattus norvegicus (Norway rat)Ki0.00030.00010.27892.8900AID50502
Cholecystokinin receptor type AHomo sapiens (human)IC50 (µMol)1.90000.00010.30381.9000AID52422
Cholecystokinin receptor type ACavia porcellus (domestic guinea pig)IC50 (µMol)1.90000.00041.13803.5000AID52422
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
neuron migrationCholecystokinin receptor type AHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayCholecystokinin receptor type AHomo sapiens (human)
axonogenesisCholecystokinin receptor type AHomo sapiens (human)
forebrain developmentCholecystokinin receptor type AHomo sapiens (human)
cholecystokinin signaling pathwayCholecystokinin receptor type AHomo sapiens (human)
G protein-coupled receptor signaling pathwayCholecystokinin receptor type AHomo sapiens (human)
cellular response to hormone stimulusCholecystokinin receptor type AHomo sapiens (human)
regulation of hormone secretionCholecystokinin receptor type AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
cholecystokinin receptor activityCholecystokinin receptor type AHomo sapiens (human)
peptide hormone bindingCholecystokinin receptor type AHomo sapiens (human)
peptide bindingCholecystokinin receptor type AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleoplasmCholecystokinin receptor type AHomo sapiens (human)
cytosolCholecystokinin receptor type AHomo sapiens (human)
plasma membraneCholecystokinin receptor type AHomo sapiens (human)
membraneCholecystokinin receptor type AHomo sapiens (human)
plasma membraneCholecystokinin receptor type AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID50502Inhibition of [125I]BH-CCK-8 binding to Cholecystokinin type A receptor of rat pancreatic tissue2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
CCK peptides with combined features of hexa- and tetrapeptide CCK-A agonists.
AID231666CCK-A selectivity is the Ratio of CCK-B to CCK-A binding affinity2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
CCK peptides with combined features of hexa- and tetrapeptide CCK-A agonists.
AID177402Ability of intraperitoneally administered compound, to inhibit food intake was measured 3 hr after feeding the rats.2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
CCK peptides with combined features of hexa- and tetrapeptide CCK-A agonists.
AID51460Binding affinity towards Cholecystokinin type B receptor in rat cortex synaptosomes using [125I]BH-CCK-8 as radioligand2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
CCK peptides with combined features of hexa- and tetrapeptide CCK-A agonists.
AID177401Ability of intraperitoneally administered compound, to inhibit food intake was measured 0.5 hr after feeding the rats.2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
CCK peptides with combined features of hexa- and tetrapeptide CCK-A agonists.
AID53040Inhibitory activity against cholecystokinin type A receptor from rat pancreas binding assay1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Analogs of CCK incorporating conformationally constrained replacements for Asp32.
AID52422Inhibitory activity against cholecystokinin type A receptor from bovine striatal binding assay1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Analogs of CCK incorporating conformationally constrained replacements for Asp32.
AID1346809Rat CCK1 receptor (Cholecystokinin receptors)1992The American journal of physiology, Jul, Volume: 263, Issue:1 Pt 2
Behavioral effects of A71623, a highly selective CCK-A agonist tetrapeptide.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's22 (81.48)18.2507
2000's3 (11.11)29.6817
2010's1 (3.70)24.3611
2020's1 (3.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.34 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (96.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]